Regensburg Center for Interventional Immunology adopts LUMICKS’ z-Movi® Cell Avidity Analyzer

Am Amsterdam, the Netherlands – May 27, 2021 –  In its effort to develop effective cellular immunotherapies for cancer treatment, the Regensburg Center for Interventional Immunology (RCI) in Germany has purchased LUMICKS’ z-Movi® Cell Avidity Analyzer. The placement highlights the promise of measuring cell avidity between immune cells and their tumor targets to improve the selection of chimeric antigen receptors (CARs) and accelerate the development of new CAR-T therapies.

The instrument has been placed in the lab of Dr. Hinrich Abken, Professor and Chair for Genetic Immunotherapy at Regensburg University. Professor Abken is a pioneer in the design and development of CAR T cells for cancer malignancies. His current work is aimed at improving T cell targeting of cancer cells and at translating these strategies into clinical trials.  

We expect to gain greater insight into the mechanism of CAR mediated tumor cell recognition and into the selection of the most potent CAR for clinical application,” Prof. Abken said. LUMICKS’ z-Movi Cell Avidity Analyzer will be used by his team to measure the binding strengths between CAR T cells and tumor cells. The instrument is intended to take part in the developmental pipeline for identifying novel therapeutic immune cell interactions that could be exploited to enhance the efficacy of adoptive cell therapy.

LUMICKS looks forward to supporting one of the leading research centers for interventional immunology in Europe.  “In this exciting time, where immunology has emerged as an essential approach to treating cancer, we are excited that RCI will be using the z-Movi to advance their immunotherapy research,” said LUMICKS CSO Dr. Andrea Candelli. “We believe the z-Movi can enable Professor Abken and his team to bring new insights into the mechanisms of adoptive cell therapy and to expedite the development of novel CAR T cell targeting strategies.


LUMICKS is a leading life science tools company that develops equipment for dynamic single-molecule and cell avidity analysis, two rapidly emerging areas in biology research and immuno-oncology.  LUMICKS’ tools allow researchers to build the crucial and as yet unfinished bridge between structure and function at both a molecular and a cellular level. This is achieved by applying and measuring forces around biological interactions, enabling the detailed real-time analysis of underlying biological mechanisms. LUMICKS’ C-Trap® Optical Tweezers – Fluorescence & Label-free Microscopy, allows scientists to analyze complex biological processes in real-time. Similarly, the z-Movi® Cell Avidity Analyzer enables the measurement and selection of immune cells based on their real-time interactions with target cells.

About RCI

The RCI Regensburg Center for Interventional Immunology, an extra-university research center, focuses on translational immunology in the fields of cancer immunotherapy, chronic inflammation and autoimmunity. Its objective is to develop effective cellular immunotherapies in these areas.

For more information contact:

Kassandra Barbetsea, media contact

+31 (0) 63 482 09 48

Joshua Young, investor contact

Join our newsletter

Get exclusive news on the latest publications, product developments, events and breakthrough science.

By submitting the form you agree to LUMICKS' privacy policy. You can revoke your consent at any time.

Download our webinar recording:


Download our Cell Therapy (CAR-T, TCR, NK) applications deck